ArticleiScience2026
IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) are widely used for advanced renal cell carcinoma (aRCC); however, predictive biomarkers of response remain insufficiently defined, and treatment resistance is common. We comprehensively analyzed clinical samples from 51 patients with aRCC treated with anti-PD-1 therapy to identify resistance factors. Immunohistochemical analysis of tissue microarrays showed no significant correlation between baseline tumor microenvironment features and therapeutic response. In contrast, peripheral blood flow cytometry demonstrated persistently elevated monocytic myeloid-derived suppressor cells (M-MDSCs) in non-responders. A next-generation patient-derived xenograft (NG-PDX) model established by co-engrafting tumor tissue and peripheral immune cells from the same patient recapitulated patient-specific tumor-immune interactions, using MHC class I/II-knockout immunodeficient mice. In this model, combined blockade of PD-1 and IL-8, a key chemokine recruiting MDSCs, tended to suppress tumor growth. These findings identify immune features associated with PD-1 resistance in aRCC and support NG-PDX models as a platform for evaluating rational immunotherapeutic combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.